345 EAST MAIN STREET, WARSAW, IN
Zimmer Biomet Holdings Enters $1.5 Billion Revolving Credit Agreement
Shareholder votes
Increases Share Repurchase Expectations — Up to $1 Billion by Year End
Announces First Quarter 2026 Financial Results
Announces Chief Financial Officer Transition
Annual Report to Security Holders
Announces Fourth Quarter and Full-Year 2025 Financial Results
Mark Bezjak Resigns from Zimmer Biomet Holdings, Effective January 16, 2026
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Certificate
Registration of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Free Writing Prospectus